Serum interleukin−21 as a biomarker for determining COVID−19 vaccination status in patients with myasthenia gravis: A cross−sectional study
NeuroMarkers · 2026-11 · 3 (4) · 100184
DOI: 10.1016/j.neumar.2026.100184 ↗Kurz gefasst
Fachartikel in der Zeitschrift NeuroMarkers, 2026-11. Verfasst von Heba Samir Abdelraheem und 3 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objectives
Coronavirus disease 2019 (COVID-19) infection has been reported to induce de novo autoimmune diseases in humans, including myasthenia gravis (MG), or trigger a relapse in such diseases. The same studies have also indicated that COVID-19 vaccination may be associated with this phenomenon. This study aimed to investigate the effects of COVID-19 infection and vaccination on disease progression in Egyptian patients with MG and the relationship between COVID-19 vaccination and interleukin-21 (IL-21) levels in patients with MG.
Methods
This cross-sectional study included 40 Egyptian patients with MG admitted to the neuromuscular clinic of Alexandria University Hospital. The clinical history of their MG disease and the history of COVID-19 infection and vaccination were evaluated, and the number of relapses due to COVID-19 infection and vaccination was recorded. Moreover, serum IL-21 levels were measured in all participants. Thirty healthy individuals were included as controls, and their serum IL-21 levels were assessed. The data collected were analyzed to determine the association between IL-21 levels and prior exposure to COVID-19.
Results
Among the 40 MG patients included in this study, 30 patients were positive for acetylcholine receptor antibodies, and 10 were negative for acetylcholine receptor antibodies. All of them were diagnosed with generalized MG. Three MG patients (7.5%) had COVID-19 infection, with two patients reporting exacerbation of their myasthenic symptoms following infection. Fifteen MG patients (37.5%) received COVID-19 vaccination, a proportion significantly lower than that observed in the healthy control group (80%). Serum IL-21 levels were significantly lower in the vaccinated patients than in the unvaccinated patients ( P = 0.024).
Conclusion
Serum IL-21 levels are significantly lower in vaccinated MG patients than in unvaccinated MG patients.
Zitieren
APA
Abdelraheem, H. S., Abdelraouf, M. H., Marouf, H. M., & Said, S. M. (2026). Serum interleukin−21 as a biomarker for determining COVID−19 vaccination status in patients with myasthenia gravis: A cross−sectional study. NeuroMarkers, 3(4), 100184. https://doi.org/10.1016/j.neumar.2026.100184
Vancouver
Abdelraheem HS, Abdelraouf MH, Marouf HM, Said SM. Serum interleukin−21 as a biomarker for determining COVID−19 vaccination status in patients with myasthenia gravis: A cross−sectional study. NeuroMarkers. 2026;3(4):100184. doi:10.1016/j.neumar.2026.100184
BibTeX
@article{Abdelraheem2026,
author = {Abdelraheem, Heba Samir and Abdelraouf, Mervat Hamed and Marouf, Hazem Mohamed and Said, Sameh Mahmoud},
title = {Serum interleukin−21 as a biomarker for determining COVID−19 vaccination status in patients with myasthenia gravis: A cross−sectional study},
journal = {NeuroMarkers},
year = {2026},
volume = {3},
number = {4},
pages = {100184},
doi = {10.1016/j.neumar.2026.100184}
}
EUVIMED